Is liver biopsy necessary during low-dose methotrexate therapy? A hepatologist's view

Forum for Nordic Dermato-Venerology

Volumn 10, Issue 1, 2005, Pages 9-12

  Christensen, Erik ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; PROBENECID; SALICYLIC ACID DERIVATIVE; SULFONAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; COST BENEFIT ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ESOPHAGUS VARICES; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HISTOLOGY; HISTOPATHOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; NAUSEA; NON INVASIVE MEASUREMENT; PERCUTANEOUS BIOPSY; PORTOSYSTEMIC ANASTOMOSIS; PRACTICE GUIDELINE; PSORIASIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM;

EID: 13744255760     PISSN: 14022915     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Zachariae H. Methotrexate for psoriasis in 2004. Forum Nord Derm Ven 2004; 9: 98-102.
2. Roenigk HH Jr, Auerbach R, Mailbach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: Consensus Conference. J Am Acad Dermatol 1998; 38: 478-485.
3. Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19: 391-399.
4. Tang H, Neuberger J. Review article: methotrexate in gastroenterology dangerous villain or simply misunderstood? Aliment Pharmacol Ther 1996; 10: 851-858.
5. Iversen P, Roholm K. On aspiration biopsy of th liver, with remarks on its diagnostic significance. Acta Med Scand 1939; 102: 1
6. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. Gut 1999; 45 (Suppl IV): IV1-IV11.
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38: 1449-1457.
8. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
9. Richard S, Guerret S, Gerard F, Tebib JG, Vignon E. Hepatic fibrosis in rheumatoid arthritis treated with methotrexate: application of a new semi-quantitative scoring system. Rheumatology 2000; 39: 50-54.
10. Bergquist SR, Felson DT, Prashker MJ, Freedberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995; 38: 326-333.
11. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004; 99: 1160-1074.
12. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores - where are we and where should we go? J Hepatol 2004; 41: 344-350.
13. Poynard T, Munreanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 2004; 50: 1344-1355.